Sandoz Brings New Generic for Firazyr, Treating Acute HAE Attacks, to US

Sandoz Brings New Generic for Firazyr, Treating Acute HAE Attacks, to US

284757

Sandoz Brings New Generic for Firazyr, Treating Acute HAE Attacks, to US

A new generic form of icatibant injection is now available in the United States to treat acute attacks of hereditary angioedema (HAE) in adults age 18 and older. The medicine was licensed to Sandoz by Slayback Pharma for commercial use in the U.S., and comes packaged in prefilled, single-use syringes containing 30 mg of the active ingredient in a 3 mL dose. It is equivalent to Takeda’s Firazyr in terms of effectiveness, safety, dosage, administration route,…

You must be logged in to read/download the full post.